ALNY
Alnylam Pharmaceuticals, Inc.
Price Chart
Latest Quote
$303.87
+0.23 (+0.08%)
Current Price
| Previous Close | $303.64 |
| Open | $304.62 |
| Day High | $306.34 |
| Day Low | $302.16 |
| Volume | 321,603 |
Stock Information
| Shares Outstanding | 133.51M |
| Total Debt | $2.97B |
| Cash Equivalents | $3.01B |
| Revenue | $4.29B |
| Net Income | $537.99M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $40.46B |
| P/E Ratio | 76.34 |
| EPS (TTM) | $3.97 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $40.42B |
| Sales | $4.29B |
| Income | $537.99M |
| Book/sh | $8.06 |
| Cash/sh | $22.54 |
| Employees | 2K |
Financial Ratios
| Quick Ratio | 2.88 |
| Current Ratio | 3.13 |
| Debt/Eq | 276.20 |
Returns & Margins
| ROA | 10.06% |
| ROE | 90.36% |
| Gross Margin | 80.83% |
| Operating Margin | 23.02% |
| Profit Margin | 12.55% |
Ownership
| Insider Ownership | 0.18% |
| Institutional Ownership | 102.06% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 21.81 |
| PEG | 0.52 |
| P/S | 9.44 |
| P/B | 37.60 |
Analyst Data
| Recommendation | buy |
| Target Price | $445.81 |
Technical Indicators
| SMA20 | $295.00 |
| SMA50 | $307.22 |
| SMA200 | $381.85 |
| RSI | 62.07 |
| ATR | 9.4164 |
| Shares Float | 132.94M |
| Short Float | 5.39% |
| Short Ratio | 4.81 |
| Volatility | 0.27 |
| Rel Volume | 1.02 |
Performance History
| Week | +0.35% |
| Month | +0.02% |
| Quarter | -5.49% |
| 6 Months | -35.97% |
| YTD | -24.27% |
| Year | -0.74% |
| 3 Years | +63.80% |
| 5 Years | +113.43% |
| 10 Years | +317.42% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-05 | $303.05 | 1,003,600 |
| 2026-06-04 | $303.64 | 1,081,400 |
| 2026-06-03 | $292.58 | 988,800 |
| 2026-06-02 | $286.12 | 1,042,500 |
| 2026-06-01 | $295.63 | 1,186,000 |
| 2026-05-29 | $301.98 | 2,278,000 |
| 2026-05-28 | $305.06 | 1,020,700 |
| 2026-05-27 | $295.63 | 629,500 |
| 2026-05-26 | $295.50 | 649,700 |
| 2026-05-22 | $297.45 | 681,300 |
| 2026-05-21 | $300.51 | 650,200 |
| 2026-05-20 | $298.48 | 799,200 |
| 2026-05-19 | $294.30 | 769,900 |
| 2026-05-18 | $286.27 | 873,400 |
| 2026-05-15 | $286.98 | 1,149,400 |
| 2026-05-14 | $293.45 | 889,700 |
| 2026-05-13 | $291.48 | 975,800 |
| 2026-05-12 | $292.03 | 826,100 |
| 2026-05-11 | $284.84 | 1,287,600 |
| 2026-05-08 | $295.05 | 926,800 |
| 2026-05-07 | $295.91 | 1,144,000 |
| 2026-05-06 | $303.00 | 1,012,300 |
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
đ° Latest News
Why Is Sarepta Therapeutics (SRPT) Down 19.9% Since Last Earnings Report?
Zacks âĸ 2026-06-05T15:30:30Z
Alnylam Pharmaceuticals (ALNY) Valuation Check As US$2b AI RNAi Collaboration With Inceptive Nucleics Gains Attention
Simply Wall St. âĸ 2026-06-05T11:13:51Z
Stocks Rebound on Strength in Banks and Managed Healthcare
Barchart âĸ 2026-06-04T20:32:37Z
JPMorgan Says Buy the Dip in These 2 Large-Cap Biotech Stocks
TipRanks âĸ 2026-06-04T17:30:00Z
Alnylam Bets on AI for Speedy RNAi Drug Discovery and Development
Zacks âĸ 2026-06-04T15:27:00Z
Stocks Mixed as Tech Weakness Weighs
Barchart âĸ 2026-06-04T15:16:14Z
Alnylam, Inceptive ink AI deal potentially worth $2B
BioPharma Dive âĸ 2026-06-04T10:42:56Z
Are Options Traders Betting on a Big Move in Alnylam Stock?
Zacks âĸ 2026-05-30T18:55:00Z
JPMorgan says large-cap biotech is back as profits and pipelines fuel upside
Investing.com âĸ 2026-05-28T20:27:17ZCiti Initiates Alnylam (ALNY) With Buy Rating
Insider Monkey âĸ 2026-05-25T18:09:04Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $681,871,000 | $323,370,000 | $310,406,000 | $168,817,000 |
| Cost Of Revenue | $681,871,000 | $323,370,000 | $310,406,000 | $168,817,000 |
| Total Revenue | $3,713,937,000 | $2,248,243,000 | $1,828,292,000 | $1,037,418,000 |
| Operating Revenue | $3,713,937,000 | $2,248,243,000 | $1,828,292,000 | $1,037,418,000 |
| Expenses | ||||
| Interest Expense | $252,627,000 | $141,858,000 | $121,221,000 | $155,968,000 |
| Total Expenses | $3,212,359,000 | $2,425,128,000 | $2,110,467,000 | $1,822,490,000 |
| Rent Expense Supplemental | $193,435,000 | $169,909,000 | $145,687,000 | $131,967,000 |
| Other Income Expense | $-37,269,000 | $-180,624,000 | $-125,682,000 | $-210,761,000 |
| Other Non Operating Income Expenses | $7,510,000 | $-6,832,000 | $-17,741,000 | $-6,204,000 |
| Net Non Operating Interest Income Expense | $-141,157,000 | $-19,866,000 | $-25,660,000 | $-131,160,000 |
| Interest Expense Non Operating | $252,627,000 | $141,858,000 | $121,221,000 | $155,968,000 |
| Operating Expense | $2,530,488,000 | $2,101,758,000 | $1,800,061,000 | $1,653,673,000 |
| General And Administrative Expense | $1,210,713,000 | $975,526,000 | $795,646,000 | $770,658,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $313,747,000 | $-278,157,000 | $-440,242,000 | $-1,131,156,000 |
| Net Interest Income | $-141,157,000 | $-19,866,000 | $-25,660,000 | $-131,160,000 |
| Interest Income | $111,470,000 | $121,992,000 | $95,561,000 | $24,808,000 |
| Normalized Income | $357,227,409 | $-150,072,296 | $-354,968,610 | $-969,555,970 |
| Net Income From Continuing And Discontinued Operation | $313,747,000 | $-278,157,000 | $-440,242,000 | $-1,131,156,000 |
| Total Operating Income As Reported | $501,578,000 | $-176,885,000 | $-282,175,000 | $-785,072,000 |
| Net Income Common Stockholders | $313,747,000 | $-278,157,000 | $-440,242,000 | $-1,131,156,000 |
| Net Income | $313,747,000 | $-278,157,000 | $-440,242,000 | $-1,131,156,000 |
| Net Income Including Noncontrolling Interests | $313,747,000 | $-278,157,000 | $-440,242,000 | $-1,131,156,000 |
| Net Income Continuous Operations | $313,747,000 | $-278,157,000 | $-440,242,000 | $-1,131,156,000 |
| Pretax Income | $323,152,000 | $-377,375,000 | $-433,517,000 | $-1,126,993,000 |
| Special Income Charges | $-42,473,000 | $0 | $0 | $-76,586,000 |
| Interest Income Non Operating | $111,470,000 | $121,992,000 | $95,561,000 | $24,808,000 |
| Operating Income | $501,578,000 | $-176,885,000 | $-282,175,000 | $-785,072,000 |
| Gross Profit | $3,032,066,000 | $1,924,873,000 | $1,517,886,000 | $868,601,000 |
| Per Share | ||||
| Diluted EPS | $2.33 | $-2.18 | $-3.52 | $-9.30 |
| Basic EPS | $2.39 | $-2.18 | $-3.52 | $-9.30 |
| Other | ||||
| Tax Effect Of Unusual Items | $-1,298,591 | $-45,707,296 | $-22,667,610 | $-42,956,970 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $676,216,000 | $-5,055,000 | $-150,301,000 | $-722,000,000 |
| Total Unusual Items | $-44,779,000 | $-173,792,000 | $-107,941,000 | $-204,557,000 |
| Total Unusual Items Excluding Goodwill | $-44,779,000 | $-173,792,000 | $-107,941,000 | $-204,557,000 |
| Reconciled Depreciation | $55,658,000 | $56,670,000 | $54,054,000 | $44,468,000 |
| EBITDA (Bullshit earnings) | $631,437,000 | $-178,847,000 | $-258,242,000 | $-926,557,000 |
| EBIT | $575,779,000 | $-235,517,000 | $-312,296,000 | $-971,025,000 |
| Diluted Average Shares | $134,684,000 | $127,651,000 | $124,906,000 | $121,689,000 |
| Basic Average Shares | $131,004,000 | $127,651,000 | $124,906,000 | $121,689,000 |
| Diluted NI Availto Com Stockholders | $313,747,000 | $-278,157,000 | $-440,242,000 | $-1,131,156,000 |
| Tax Provision | $9,405,000 | $-99,218,000 | $6,725,000 | $4,163,000 |
| Other Special Charges | $42,473,000 | - | - | $76,586,000 |
| Gain On Sale Of Security | $-2,306,000 | $-173,792,000 | $-107,941,000 | $-127,971,000 |
| Research And Development | $1,319,775,000 | $1,126,232,000 | $1,004,415,000 | $883,015,000 |
| Selling General And Administration | $1,210,713,000 | $975,526,000 | $795,646,000 | $770,658,000 |
| Other Gand A | $348,976,000 | $274,539,000 | $226,664,000 | $226,941,000 |
| Rent And Landing Fees | $193,435,000 | $169,909,000 | $145,687,000 | $131,967,000 |
| Salaries And Wages | $668,302,000 | $531,078,000 | $423,295,000 | $411,750,000 |
Fetched: 2026-05-30
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $789,176,000 | $67,088,000 | $-220,644,000 | $-158,223,000 |
| Total Assets | $4,966,331,000 | $4,239,983,000 | $3,829,880,000 | $3,546,359,000 |
| Total Non Current Assets | $915,669,000 | $944,698,000 | $847,183,000 | $854,112,000 |
| Other Non Current Assets | $81,631,000 | $133,903,000 | $111,293,000 | $115,482,000 |
| Non Current Deferred Assets | $125,975,000 | $116,863,000 | $10,101,000 | - |
| Non Current Deferred Taxes Assets | $125,975,000 | $116,863,000 | $10,101,000 | - |
| Current Assets | $4,050,662,000 | $3,295,285,000 | $2,982,697,000 | $2,692,247,000 |
| Other Current Assets | $281,892,000 | $116,964,000 | $126,382,000 | $132,916,000 |
| Inventory | $82,719,000 | $78,509,000 | $89,146,000 | $128,962,000 |
| Receivables | $777,567,000 | $405,308,000 | $327,787,000 | $237,963,000 |
| Accounts Receivable | $777,567,000 | $405,308,000 | $327,787,000 | $237,963,000 |
| Cash Cash Equivalents And Short Term Investments | $2,908,484,000 | $2,694,504,000 | $2,439,382,000 | $2,192,406,000 |
| Cash And Cash Equivalents | $1,657,250,000 | $966,428,000 | $812,688,000 | $866,394,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $1,278,389,000 | $1,296,048,000 | $1,305,387,000 | $1,320,248,000 |
| Long Term Debt And Capital Lease Obligation | $1,232,871,000 | $1,254,162,000 | $1,263,877,000 | $1,278,281,000 |
| Long Term Debt | $1,007,784,000 | $1,024,621,000 | $1,020,776,000 | $1,016,942,000 |
| Current Debt And Capital Lease Obligation | $45,518,000 | $41,886,000 | $41,510,000 | $41,967,000 |
| Net Debt | - | $58,193,000 | $208,088,000 | $150,548,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $4,177,155,000 | $4,172,895,000 | $4,050,524,000 | $3,704,582,000 |
| Total Non Current Liabilities Net Minority Interest | $2,710,806,000 | $2,986,623,000 | $3,082,738,000 | $2,936,667,000 |
| Other Non Current Liabilities | $1,477,935,000 | $1,339,322,000 | $1,630,686,000 | $1,464,595,000 |
| Derivative Product Liabilities | $0 | $393,139,000 | - | - |
| Current Liabilities | $1,466,349,000 | $1,186,272,000 | $967,786,000 | $767,915,000 |
| Other Current Liabilities | $220,068,000 | $206,798,000 | $54,991,000 | $40,289,000 |
| Current Deferred Liabilities | $4,845,000 | $55,481,000 | $102,753,000 | $42,105,000 |
| Payables And Accrued Expenses | $938,721,000 | $667,708,000 | $646,362,000 | $512,864,000 |
| Payables | $115,721,000 | $88,415,000 | $55,519,000 | $98,094,000 |
| Accounts Payable | $115,721,000 | $88,415,000 | $55,519,000 | $98,094,000 |
| Non Current Deferred Liabilities | - | $0 | $188,175,000 | $193,791,000 |
| Equity | ||||
| Common Stock Equity | $789,176,000 | $67,088,000 | $-220,644,000 | $-158,223,000 |
| Total Equity Gross Minority Interest | $789,176,000 | $67,088,000 | $-220,644,000 | $-158,223,000 |
| Stockholders Equity | $789,176,000 | $67,088,000 | $-220,644,000 | $-158,223,000 |
| Gains Losses Not Affecting Retained Earnings | $-20,097,000 | $-34,518,000 | $-23,375,000 | $-44,654,000 |
| Other Equity Adjustments | $-20,097,000 | $-34,518,000 | $-23,375,000 | $-44,654,000 |
| Retained Earnings | $-6,702,524,000 | $-7,287,748,000 | $-7,009,591,000 | $-6,569,349,000 |
| Other | ||||
| Ordinary Shares Number | $132,376,000 | $129,294,000 | $125,794,000 | $123,925,000 |
| Share Issued | $132,376,000 | $129,294,000 | $125,794,000 | $123,925,000 |
| Tangible Book Value | $789,176,000 | $67,088,000 | $-220,644,000 | $-158,223,000 |
| Invested Capital | $1,796,960,000 | $1,091,709,000 | $800,132,000 | $858,719,000 |
| Working Capital | $2,584,313,000 | $2,109,013,000 | $2,014,911,000 | $1,924,332,000 |
| Capital Lease Obligations | $270,605,000 | $271,427,000 | $284,611,000 | $303,306,000 |
| Total Capitalization | $1,796,960,000 | $1,091,709,000 | $800,132,000 | $858,719,000 |
| Additional Paid In Capital | $7,510,473,000 | $7,388,061,000 | $6,811,063,000 | $6,454,540,000 |
| Capital Stock | $1,324,000 | $1,293,000 | $1,259,000 | $1,240,000 |
| Common Stock | $1,324,000 | $1,293,000 | $1,259,000 | $1,240,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $225,087,000 | $229,541,000 | $243,101,000 | $261,339,000 |
| Current Deferred Revenue | $4,845,000 | $55,481,000 | $102,753,000 | $42,105,000 |
| Current Capital Lease Obligation | $45,518,000 | $41,886,000 | $41,510,000 | $41,967,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $257,197,000 | $214,399,000 | $122,170,000 | $130,690,000 |
| Current Accrued Expenses | $823,000,000 | $579,293,000 | $590,843,000 | $414,770,000 |
| Net PPE | $708,063,000 | $693,932,000 | $725,789,000 | $738,630,000 |
| Accumulated Depreciation | $-322,700,000 | $-270,364,000 | $-223,076,000 | $-173,450,000 |
| Gross PPE | $1,030,763,000 | $964,296,000 | $948,865,000 | $912,080,000 |
| Leases | $241,077,000 | $236,686,000 | $235,411,000 | $230,848,000 |
| Construction In Progress | $40,954,000 | $7,674,000 | $30,099,000 | $14,595,000 |
| Other Properties | $384,794,000 | $362,167,000 | $354,855,000 | $343,033,000 |
| Machinery Furniture Equipment | $57,240,000 | $54,181,000 | $47,769,000 | $45,202,000 |
| Buildings And Improvements | $297,618,000 | $294,508,000 | $271,651,000 | $269,322,000 |
| Land And Improvements | $9,080,000 | $9,080,000 | $9,080,000 | $9,080,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $1,251,234,000 | $1,728,076,000 | $1,626,694,000 | $1,326,012,000 |
| Non Current Deferred Revenue | - | $0 | $188,175,000 | $193,791,000 |
| Treasury Shares Number | - | - | $0 | - |
| Inventories Adjustments Allowances | - | - | - | $-32,700,000 |
| Other Inventories | - | - | - | $-42,000 |
| Finished Goods | - | - | - | $25,606,000 |
| Work In Process | - | - | - | $113,783,000 |
| Raw Materials | - | - | - | $22,315,000 |
Fetched: 2026-05-30
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $465,383,000 | $-42,589,000 | $41,945,000 | $-613,333,000 |
| Operating Activities | ||||
| Operating Cash Flow | $524,080,000 | $-8,312,000 | $104,156,000 | $-541,274,000 |
| Cash Flow From Continuing Operating Activities | $524,080,000 | $-8,312,000 | $104,156,000 | $-541,274,000 |
| Operating Gains Losses | $2,306,000 | $173,792,000 | $107,941,000 | $204,557,000 |
| Investing Activities | ||||
| Capital Expenditure | $-58,697,000 | $-34,277,000 | $-62,211,000 | $-72,059,000 |
| Investing Cash Flow | $436,329,000 | $-116,840,000 | $-336,350,000 | $169,354,000 |
| Cash Flow From Continuing Investing Activities | $436,329,000 | $-116,840,000 | $-336,350,000 | $169,354,000 |
| Net Other Investing Changes | $-2,150,000 | $-19,317,000 | $-4,438,000 | $-13,194,000 |
| Financing Activities | ||||
| Financing Cash Flow | $-305,190,000 | $294,159,000 | $172,131,000 | $425,753,000 |
| Cash Flow From Continuing Financing Activities | $-305,190,000 | $294,159,000 | $172,131,000 | $425,753,000 |
| Net Other Financing Charges | $-10,686,000 | $-8,792,000 | $24,667,000 | $-87,611,000 |
| Issuance Of Capital Stock | - | - | - | $0 |
| Net Common Stock Issuance | - | - | - | $0 |
| Common Stock Issuance | - | - | - | $0 |
| Other | ||||
| Repayment Of Debt | $-1,190,224,000 | $0 | $0 | $-762,107,000 |
| Issuance Of Debt | $645,692,000 | $0 | $0 | $1,016,111,000 |
| Interest Paid Supplemental Data | $218,707,000 | $67,578,000 | $32,118,000 | $45,235,000 |
| End Cash Position | $1,658,807,000 | $968,652,000 | $814,884,000 | $868,556,000 |
| Beginning Cash Position | $968,652,000 | $814,884,000 | $868,556,000 | $822,153,000 |
| Effect Of Exchange Rate Changes | $34,936,000 | $-15,239,000 | $6,391,000 | $-7,430,000 |
| Changes In Cash | $655,219,000 | $169,007,000 | $-60,063,000 | $53,833,000 |
| Proceeds From Stock Option Exercised | $250,028,000 | $302,951,000 | $147,464,000 | $259,360,000 |
| Net Issuance Payments Of Debt | $-544,532,000 | $0 | $0 | $254,004,000 |
| Net Long Term Debt Issuance | $-544,532,000 | $0 | $0 | $254,004,000 |
| Long Term Debt Payments | $-1,190,224,000 | $0 | $0 | $-762,107,000 |
| Long Term Debt Issuance | $645,692,000 | $0 | $0 | $1,016,111,000 |
| Net Investment Purchase And Sale | $497,176,000 | $-63,246,000 | $-269,701,000 | $254,607,000 |
| Sale Of Investment | $1,802,257,000 | $1,571,665,000 | $1,553,800,000 | $2,231,568,000 |
| Purchase Of Investment | $-1,305,081,000 | $-1,634,911,000 | $-1,823,501,000 | $-1,976,961,000 |
| Net PPE Purchase And Sale | $-58,697,000 | $-34,277,000 | $-62,211,000 | $-72,059,000 |
| Purchase Of PPE | $-58,697,000 | $-34,277,000 | $-62,211,000 | $-72,059,000 |
| Change In Working Capital | $-444,782,000 | $-214,084,000 | $57,261,000 | $7,618,000 |
| Change In Other Working Capital | $-50,635,000 | $-235,446,000 | $55,022,000 | $-65,911,000 |
| Change In Payables And Accrued Expense | $75,066,000 | $91,093,000 | $80,840,000 | $191,769,000 |
| Change In Payable | $75,066,000 | $91,093,000 | $80,840,000 | $191,769,000 |
| Change In Account Payable | $75,066,000 | $91,093,000 | $80,840,000 | $191,769,000 |
| Change In Prepaid Assets | $-117,724,000 | $3,229,000 | $-9,029,000 | $-38,507,000 |
| Change In Inventory | $8,474,000 | $13,590,000 | $18,367,000 | $-34,136,000 |
| Change In Receivables | $-359,963,000 | $-86,550,000 | $-87,939,000 | $-45,597,000 |
| Changes In Account Receivables | $-359,963,000 | $-86,550,000 | $-87,939,000 | $-45,597,000 |
| Other Non Cash Items | $251,114,000 | $88,145,000 | $104,175,000 | $104,023,000 |
| Stock Based Compensation | $348,235,000 | $272,084,000 | $221,680,000 | $230,649,000 |
| Deferred Tax | $-2,198,000 | $-106,762,000 | $-713,000 | $-1,433,000 |
| Deferred Income Tax | $-2,198,000 | $-106,762,000 | $-713,000 | $-1,433,000 |
| Depreciation Amortization Depletion | $55,658,000 | $56,670,000 | $54,054,000 | $44,468,000 |
| Depreciation And Amortization | $55,658,000 | $56,670,000 | $54,054,000 | $44,468,000 |
| Gain Loss On Investment Securities | $2,306,000 | $173,792,000 | $107,941,000 | $127,971,000 |
| Net Income From Continuing Operations | $313,747,000 | $-278,157,000 | $-440,242,000 | $-1,131,156,000 |
| Income Tax Paid Supplemental Data | - | $14,360,000 | $6,021,000 | $2,654,000 |
| Change In Other Current Liabilities | - | - | $-46,502,000 | $-43,171,000 |
| Depreciation | - | - | $97,031,000 | $85,550,000 |
Fetched: 2026-05-30